PMID- 36998008
OWN - NLM
STAT- MEDLINE
DCOM- 20230403
LR  - 20230406
IS  - 2050-6511 (Electronic)
IS  - 2050-6511 (Linking)
VI  - 24
IP  - 1
DP  - 2023 Mar 30
TI  - Controlled release of silica-coated insulin-loaded chitosan nanoparticles as a 
      promising oral administration system.
PG  - 21
LID - 10.1186/s40360-023-00662-1 [doi]
LID - 21
AB  - BACKGROUND: Oral insulin administration has recently become one of the most 
      exciting research subjects. Different approaches have been carried out to get an 
      effective oral insulin delivery system using nanotechnology. The development of a 
      delivery system that overcomes the difficulties of oral insulin administration, 
      achieving high stability and minimal side effects, is still an urgent need. 
      Therefore, this study is considered one of the efforts to design a new 
      prospective drug delivery nano-composite (silica-coated chitosan-dextran sulfate 
      nanoparticles). METHODS: Chitosan-dextran sulfate nanoparticles (CS-DS NPs) were 
      prepared via a complex coacervation method and then coated with silica. Uncoated 
      and silica-coated CS-DS NPs were physically characterized via different 
      techniques. Transmission electron microscopy (TEM), scanning electron microscopy 
      (SEM), energy-dispersive X-ray (EDX) analysis, and atomic force microscopy (AFM) 
      have been used to investigate the chemical elements, size, morphology, and 
      surface properties of the prepared formulations. Differential scanning 
      calorimetry (DSC) to assess the thermal properties of formed nano-formulations. 
      Fourier transform infrared (FT-IR) spectroscopy investigated the silica coat and 
      chitosan interaction. The encapsulation efficiency was evaluated using 
      high-performance liquid chromatography (HPLC) analysis. The insulin release 
      profile of nano-formulations was performed with and without silica coat at two 
      different pHs (5.5,7), nearly simulating the environment of the gastrointestinal 
      tract (GIT). RESULTS: The silica-coated CS-DS NPs revealed interesting 
      physicochemical properties exemplified by suitable core particle size obtained by 
      TEM images (145.31 +/- 33.15 nm), hydrodynamic diameter (210 +/- 21 nm), high 
      stability indicated by their zeta potential value (-32 +/- 3.2 mV), and adequate 
      surface roughness assessed by AFM. The encapsulation efficiency of insulin-loaded 
      chitosan nanoparticles (ICN) was (66.5%) higher than that of insulin-chitosan 
      complex nanoparticles (ICCN). The silica-coated ICN demonstrated a controlled 
      insulin release profile at pHs (5.5 and 7) compared with uncoated ICN. 
      CONCLUSION: The silica-coated ICN can be an efficient candidate as a desired oral 
      delivery system, overcoming the common obstacles of peptides and proteins 
      delivery and achieving high stability and controlled release for further 
      applications.
CI  - (c) 2023. The Author(s).
FAU - Fathy, Mohamed M
AU  - Fathy MM
AD  - Biophysics Department, Faculty of Science, Cairo University, Giza, Egypt.
FAU - Hassan, Asmaa A
AU  - Hassan AA
AD  - Biophysics Department, Faculty of Science, Cairo University, Giza, Egypt.
FAU - Elsayed, Anwar A
AU  - Elsayed AA
AD  - Biophysics Department, Faculty of Science, Cairo University, Giza, Egypt.
FAU - Fahmy, Heba M
AU  - Fahmy HM
AD  - Biophysics Department, Faculty of Science, Cairo University, Giza, Egypt. 
      hfahmy@sci.cu.edu.eg.
LA  - eng
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
DEP - 20230330
PL  - England
TA  - BMC Pharmacol Toxicol
JT  - BMC pharmacology & toxicology
JID - 101590449
RN  - 0 (Insulin)
RN  - 0 (Delayed-Action Preparations)
RN  - 9012-76-4 (Chitosan)
RN  - 7631-86-9 (Silicon Dioxide)
RN  - 9042-14-2 (Dextran Sulfate)
SB  - IM
MH  - Humans
MH  - Insulin
MH  - Delayed-Action Preparations
MH  - *Chitosan/chemistry
MH  - Silicon Dioxide/chemistry
MH  - Spectroscopy, Fourier Transform Infrared
MH  - Dextran Sulfate
MH  - *Nanoparticles
MH  - Administration, Oral
PMC - PMC10064556
OTO - NOTNLM
OT  - Drug release test
OT  - Insulin-loaded chitosan nanoparticles
OT  - Oral administration
OT  - Silica coat
COIS- The authors declare that they have no competing interests.
EDAT- 2023/03/31 06:00
MHDA- 2023/04/03 06:42
PMCR- 2023/03/30
CRDT- 2023/03/30 23:39
PHST- 2022/06/02 00:00 [received]
PHST- 2023/03/10 00:00 [accepted]
PHST- 2023/04/03 06:42 [medline]
PHST- 2023/03/30 23:39 [entrez]
PHST- 2023/03/31 06:00 [pubmed]
PHST- 2023/03/30 00:00 [pmc-release]
AID - 10.1186/s40360-023-00662-1 [pii]
AID - 662 [pii]
AID - 10.1186/s40360-023-00662-1 [doi]
PST - epublish
SO  - BMC Pharmacol Toxicol. 2023 Mar 30;24(1):21. doi: 10.1186/s40360-023-00662-1.